Abstract Details
|
Jeffrey M. Gelfand, MD, MS, FAAN
(University of California, San Francisco)
PRESENTER |
Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities. |
| Carolyn Fredericks, MD (Yale School of Medicine, Department of Neurology) | The institution of Dr. Fredericks has received research support from Alzheimer's Association. The institution of Dr. Fredericks has received research support from National Institute on Aging. |
| Natasha Rabinowitz | No disclosure on file |
| Katherine P. Rankin, PhD (University of California San Francisco) | The institution of Dr. Rankin has received research support from Marcus Foundation. |
| No disclosure on file | |
| No disclosure on file | |
| Joseph J. Higgins, MD, FAAN (AEGRIS LLC) | No disclosure on file |
| No disclosure on file | |
| Bruce L. Miller, MD, FAAN (University of California, San Francisco) | Dr. Miller has nothing to disclose. |
| Howard J. Rosen, MD (UCSF) | Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities. |
| Michael D. Geschwind, MD, PhD, FAAN (UCSF) | Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc.. |